VC Split Rock backs off of med tech investing

Venture capital outfit Split Rock Partners is planning to abandon the medical device industry, Forbes reports, looking to ditch healthcare investments and refocus on Internet services. The generalist investor has long diversified its bets across the technology space, but Managing Director Michael Gorman told Forbes that the challenging market for med tech has made the sector less attractive. Split Rock's healthcare portfolio includes Ardian, Santarus and Twelve. Article

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.